811240--3/17/2008--BIOLASE_TECHNOLOGY

related topics

{product, liability, claim}

{customer, product, revenue}

{product, market, service}

{acquisition, growth, future}

{property, intellectual, protect}

{regulation, change, law}

{product, candidate, development}

{cost, operation, labor}

{operation, international, foreign}

{financial, litigation, operation}

{personnel, key, retain}

{operation, natural, condition}

{condition, economic, financial}

{tax, income, asset}

{gas, price, oil}

{stock, price, operating}

{control, financial, internal}

{provision, law, control}

{stock, price, share}

{regulation, government, change}

Fluctuations in our revenue and operating results on a quarterly and annual basis could cause the market price of our common stock to decline. Any failure to significantly expand sales of our products will negatively impact our business. Our distributors may cancel, reduce or delay orders of our products, any of which could reduce our revenue. Components used in our products are complex in design and any defects may not be discovered prior to shipment to customers, which could result in warranty obligations, reducing our revenue and increasing our cost. We must continue to procure materials and components on commercially reasonable terms and on a timely basis to manufacture our products profitably. We have some single-source suppliers. We may not be able to compete successfully, which will cause our revenue and market share to decline. Rapidly changing standards and competing technologies could harm demand for our products or result in significant additional costs. Any problems that we experience with our manufacturing operations may harm our business. Changes in government regulation or the inability to obtain or maintain necessary government approvals could harm our business. Regulatory proceedings relating to the restatement of our consolidated financial statements could divert management s attention and resources. We may have difficulty managing any growth that we might experience. If we fail to secure or protect our intellectual property rights, competitors may be able to use our technologies, which could weaken our competitive position, reduce our revenue or increase our costs. We may be sued by third parties for alleged infringement of their proprietary rights. We have significant international sales and are subject to risks associated with operating in international markets. Our products are subject to recall even after receiving FDA clearance or approval, which would harm our reputation, business and financial results. We may not successfully address problems encountered in connection with any future acquisition. If our customers cannot obtain third party reimbursement for their use of our products, they may be less inclined to purchase our products. Material increases in interest rates or negative changes in credit availability may harm our sales. Product liability claims against us could be costly and could harm our reputation. Our operations are consolidated primarily in one facility. A disaster at this facility is possible and could result in a prolonged interruption of our business. Our ability to use net operating loss carryforwards may be limited. Changes in our assumptions with respect to uncertain tax positions may have an adverse effect on our consolidated results of operations. In certain circumstances we may be required to return a portion of the $3.0 million license payment we received from Procter Gamble in connection with our entering into a definitive agreement relating to our intellectual property. Our business is capital intensive and the failure to obtain capital could require that we curtail capital expenditures. Our charter documents and Delaware law may inhibit a takeover that our stockholders consider favorable and could also limit the price of our stock. Our common stock could be diluted by the conversion of outstanding convertible securities. We may not be able to maintain effective internal controls. If future data proves to be inconsistent with our clinical results, our revenues may decline. If we are unable to attract and retain personnel necessary to operate our business, our ability to develop and market our products successfully could be harmed. Any failure in our efforts to train dental practitioners could reduce the market acceptance of our Waterlase system and reduce our revenues. We spend considerable time and money complying with federal, state and foreign regulations and, if we are unable to fully comply with such regulations, we could face substantial penalties.

Full 10-K form ▸

811240--3/17/2008--BIOLASE_TECHNOLOGY_INC